Overactive Bladder - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 110
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OB23D9F437DEN
Leaflet:

Download PDF Leaflet

Overactive Bladder - Pipeline Review, H2 2017
Overactive Bladder - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2017, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 5, 6, 5, 3, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Overactive Bladder - Overview
Overactive Bladder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Overactive Bladder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Overactive Bladder - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allergan Plc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
FemmePharma Global Healthcare Inc
Hanmi Pharmaceuticals Co Ltd
Hydra Biosciences Inc
Ion Channel Innovations LLC
Ipsen SA
Juniper Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Ono Pharmaceutical Co Ltd
Recordati SpA
Taiho Pharmaceutical Co Ltd
Taris Biomedical LLC
TheraVida Inc
Toray Industries Inc
XuanZhu Pharma Co Ltd
Overactive Bladder - Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
abobotulinumtoxinA - Drug Profile
ADX-71441 - Drug Profile
AK-14 - Drug Profile
DA-8010 - Drug Profile
DFL-23448 - Drug Profile
fadanafil - Drug Profile
fesoterodine - Drug Profile
HC-067047 - Drug Profile
ICE-3682 - Drug Profile
KPR-2579 - Drug Profile
mirabegron ER - Drug Profile
onabotulinumtoxinA - Drug Profile
onabotulinumtoxinA - Drug Profile
onabotulinumtoxinA SR - Drug Profile
ONO-8577 - Drug Profile
oxybutynin chloride - Drug Profile
oxybutynin chloride - Drug Profile
Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile
pVAX-hSlo - Drug Profile
REC-0438 - Drug Profile
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile
Small Molecules to Antagonize PTGER1 for Overactive Bladder - Drug Profile
solabegron hydrochloride - Drug Profile
solabegron hydrochloride MR - Drug Profile
solifenacin succinate - Drug Profile
solifenacin succinate - Drug Profile
TAC-302 - Drug Profile
THVD-201 - Drug Profile
trospium chloride - Drug Profile
udenafil - Drug Profile
vibegron - Drug Profile
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Overactive Bladder, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2017
Overactive Bladder - Pipeline by Allergan Plc, H2 2017
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp, H2 2017
Overactive Bladder - Pipeline by Astellas Pharma Inc, H2 2017
Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H2 2017
Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H2 2017
Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H2 2017
Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Overactive Bladder - Pipeline by Hydra Biosciences Inc, H2 2017
Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H2 2017
Overactive Bladder - Pipeline by Ipsen SA, H2 2017
Overactive Bladder - Pipeline by Juniper Pharmaceuticals Inc, H2 2017
Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H2 2017
Overactive Bladder - Pipeline by Merck & Co Inc, H2 2017
Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H2 2017
Overactive Bladder - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Overactive Bladder - Pipeline by Recordati SpA, H2 2017
Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Overactive Bladder - Pipeline by Taris Biomedical LLC, H2 2017
Overactive Bladder - Pipeline by TheraVida Inc, H2 2017
Overactive Bladder - Pipeline by Toray Industries Inc, H2 2017
Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Overactive Bladder - Dormant Projects, H2 2017
Overactive Bladder - Dormant Projects, H2 2017 (Contd.1), H2 2017
Overactive Bladder - Dormant Projects, H2 2017 (Contd.2), H2 2017
Overactive Bladder - Dormant Projects, H2 2017 (Contd.3), H2 2017
Overactive Bladder - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Overactive Bladder, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Addex Therapeutics Ltd
Allergan Plc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
FemmePharma Global Healthcare Inc
Hanmi Pharmaceuticals Co Ltd
Hydra Biosciences Inc
Ion Channel Innovations LLC
Ipsen SA
Juniper Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Ono Pharmaceutical Co Ltd
Recordati SpA
Taiho Pharmaceutical Co Ltd
Taris Biomedical LLC
TheraVida Inc
Toray Industries Inc
XuanZhu Pharma Co Ltd
Skip to top


Overactive Bladder Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 226 pages

Ask Your Question

Overactive Bladder - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: